Sutthichai Nakphook

Dr. Sutthichai Nakphook

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 March 2021 in Influenza and Other Respiratory Viruses
Verified
Journal Article
Open access
PDF file
PPPrabda Praphasiri
Prabda Praphasiri
MSManash Shrestha
Manash Shrestha
JPJayanton Patumanond
Jayanton Patumanond
SNSutthichai Nakphook
Sutthichai Nakphook
SCSutthinan Chawalchitiporn
Sutthinan Chawalchitiporn
KPKriengkrai Prasert
Kriengkrai Prasert
Background: Adults with cardiopulmonary conditions may be at increased risk of influenza and respiratory syncytial virus (RSV) infection, but it is not well‐established and few data are available from middle‐income countries.Methods: Using data from a prospective cohort study of influenza vaccine effectiveness, we estimated and compared the incidences of influenza and RSV between community‐dwelling Thai adults aged ≥ 65 years with and without cardiopulmonary conditions. During May 2015‐May 2017, older adults in a rural province in Thailand were followed‐up with weekly surveillance for acute respiratory illness (ARI), defined broadly as new onset or worsening of cough with or without fever, and hospitalized ARI. When ill, nasal self‐swabs and/or nasopharyngeal swabs were collected for reverse‐transcription polymerase chain reaction testing. We used Poisson regression to calculate incidence rate ratios (IRR), adjusting for age, sex, current smoking, number of hospital visits, weekly influenza activity, and influenza vaccination.Results: Overall, 3220 adults with a median age of 71 years (IQR 68‐76) were enrolled; 1324 (41.1%) were male; and 313 (9.7%) had ≥1 underlying cardiopulmonary condition, most commonly chronic obstructive pulmonary disease (131; 41.2%) or asthma (73; 23.3%). Participants with cardiopulmonary conditions had higher incidences of ARI, influenza, and RSV than those without (Adjusted IRR: 1.84, 95% CI 1.64‐2.07; 1.86, 95% CI 1.07‐3.26; 2.04, 95% CI 1.11‐3.76, respectively).Conclusion: Older adults in rural Thailand with cardiopulmonary conditions have increased rates of ARI, influenza, and RSV infections. Our findings support efforts to ensure this population has access to influenza vaccines and other respiratory illness prevention measures.

28 June 2024 in Vaccine: X
Verified
Journal Article
Open access
KPKriengkrai Prasert
Kriengkrai Prasert
PPPrabda Praphasiri
Prabda Praphasiri
SNSutthichai Nakphook
Sutthichai Nakphook
DDDarunee Ditsungnoen
Darunee Ditsungnoen
PSPatranuch Sapchookul
Patranuch Sapchookul
CPChakrarat Pittayawonganon
Chakrarat Pittayawonganon
• Influenza circulation in Thailand resumed in 2022 with a typical seasonal pattern. • Most cases were caused by influenza A/H3N2 (predominantly A/Darwin/9/2021(H3N2), clade 3C.2a1b.2a.2). • Influenza vaccine was 51% effective against medically-attended illness in Thailand.

9 June 2021 in PLOS ONE
Verified
Journal Article
Open access
PDF file
SNSutthichai Nakphook
Sutthichai Nakphook
JPJayanton Patumanond
Jayanton Patumanond
MSManash Shrestha
Manash Shrestha
KPKriengkrai Prasert
Kriengkrai Prasert
MCMalinee Chittaganpitch
Malinee Chittaganpitch
PPPrabda Praphasiri
Prabda Praphasiri
Background: We compared influenza antibody titers among vaccinated and unvaccinated pregnant and non-pregnant women. Methods: During 1st June– 30th September 2018, four groups of cohort participants—vaccinated pregnant, unvaccinated pregnant, vaccinated non-pregnant, and unvaccinated non-pregnant women were selected by matching age, gestational age, and the week of vaccination. Serum antibody titers against each strain of 2018 Southern Hemisphere inactivated trivalent influenza vaccine (IIV3) were assessed by hemagglutination inhibition (HI) assay on Day 0 (pre-vaccination) and Day 28 (one month post-vaccination) serum samples. Geometric mean titer (GMT), GMT ratio (GMR), seroconversion (defined as ≥4 fold increase in HI titer), and seroprotection (i.e. HI titer ≥1:40) were compared across the study groups using multilevel regression analyses, controlling for previous year vaccination from medical records and baseline antibody levels. Results: A total of 132 participants were enrolled in the study (33 in each of the four study groups). The baseline GMTs for influenza A(H1N1), A(H3N2), and B vaccine strains were not significantly different among all four groups (all p-values >0.05). After one month, both vaccinated groups had significantly higher GMT, GMR, seroconversion, and seroprotection than their unvaccinated controls (all p-values 0.05). Conclusions: The 2018 seasonal IIV3 was immunogenic against all three vaccine strains and pregnancy did not seem to alter the immune response to IIV3. These findings support the current influenza vaccination recommendations for pregnant women.

19 May 2023 in Heliyon
Verified
Journal Article
Open access
KAKamolthip Atsawawaranunt
Kamolthip Atsawawaranunt
KTKhammakorn Thiangthangthum
Khammakorn Thiangthangthum
SSSomrak Sirikhetkon
Somrak Sirikhetkon
PJPromporn Jampathong
Promporn Jampathong
AKAmornmas Kongklieng
Amornmas Kongklieng
AMAnek Mungaomklang
Anek Mungaomklang
High COVID-19 transmission among household (HH) contacts of infected cases were reported with seroprevalence varying from 5.5% to 57.2% worldwide. Data on seroprevalence among HH contacts and factors associated with seropositivity in Thailand are limited. To determine the seroprevalence and factors associated with anti-SARS-CoV-2 antibodies among HH contacts of COVID-19 confirmed cases. Data on confirmed COVID-19 cases (primary cases) in Bangkok from March 2020–July 2021 were retrieved from Institute for Urban Disease Control and Prevention. Primary cases were contacted within 14 days of testing positive for permission to contact their HH contacts via telephone. HH contacts were then recruited to complete questionnaires about demographics, and risk factors and blood was collected and tested for total immunoglobulin antibody against SARS-CoV-2 spike S1 protein. Factors associated with seropositivity were analysed by logistic regression. Eligible participants of 452 HH contacts of infected cases in Bangkok were contacted. Seroprevalence was 20.5% among HH contacts. Factors associated with seropositivity after multivariate analysis were relationship to index case (being other relatives to index case (other than close relatives/spouse) [aOR 4.04, 95% CI; 1.15, 14.14, p.029] and being a co-worker to index cases [aOR 0.16, 95% CI; 0.045, 0.60, p.006]), always staying in the same room with index case [aOR 5.64, 95% CI; 1.95, 16.34, p.001], sharing utensil [aOR 0.25, 95% CI; 0.074, 0.82, p.023], and participation in leisure activities together with index case [aOR 4.77, 95% CI; 1.47, 15.51, p.009]. Serological investigation can be used in detecting COVID-19 infection in conjunction with other molecular techniques. It is a useful tool for studies on seroprevalence in a population as well as seroconversion after a vaccination campaign. Sharing living environments are associated with seropositivity in HH contacts. Nevertheless, individual practices can be affected by awareness, cultural differences, and control measures implemented by each country.

28 May 2026 in Vaccines
Verified
Journal Article
Open access
PDF file
KPKriengkrai Prasert
Kriengkrai Prasert
SNSutthichai Nakphook
Sutthichai Nakphook
JKJiraphut Kittiwatanachod
Jiraphut Kittiwatanachod
KSKanlaya Sornwong
Kanlaya Sornwong
SNSuriya Naosri
Suriya Naosri
PPPrabda Praphasiri
Prabda Praphasiri
Background/Objectives: HXP-GPOVac is a locally produced, inactivated Newcastle disease virus-based (NDV-HXP-S) COVID-19 vaccine manufactured in Thailand. This phase II trial compared its safety and immunogenicity with the mRNA vaccine BNT162b2 in adults aged 18–75 years. Methods: In this randomized, double-blind, active-controlled trial registered with the Thai Clinical Trials Registry (TCTR20220819003), 300 participants were assigned 3:1 to receive HXP-GPOVac or BNT162b2 on Days 1 and 29. Solicited adverse events (AEs) were recorded for 7 days after each dose, AEs were summarized through 28 days after each dose, and serious adverse events (SAEs), medically attended AEs (MAAEs), and adverse events of special interest (AESIs) were collected through Day 197. Humoral immunogenicity was assessed by pseudovirus 50% neutralization titers (NT50) and anti-spike IgG concentrations at baseline, Day 29, Day 43, and Day 197. Seroconversion was defined as a ≥4-fold increase from baseline. A predefined subset underwent interferon-γ (IFN-γ) and interleukin-5 (IL-5) ELISpot assays to assess cell-mediated immune responses. The primary immunogenicity analysis assessed non-inferiority of HXP-GPOVac compared with BNT162b2 based on the NT50 geometric mean titer ratio, with a prespecified non-inferiority margin of 0.5. Results: Solicited AEs were predominantly mild and occurred more frequently after the first dose in both groups; one or more solicited local or systemic AEs were reported by 23.7% (95% CI: 18.3–29.8) of HXP-GPOVac recipients and 44.7% (95% CI: 33.3–56.6) of BNT162b2 recipients after the first dose. AEs through 28 days after vaccination and SAEs were uncommon; MAAEs occurred in 17.0% of HXP-GPOVac recipients and 22.4% of BNT162b2 recipients, and none were considered related to vaccination. In the HXP-GPOVac group, NT50 geometric mean titers increased from 5.6 at baseline to 65.5 at Day 29 and 505 at Day 43, declining to 63.6 at Day 197. Anti-spike IgG geometric mean concentrations rose from 7.5 BAU/mL at baseline to 102.7 BAU/mL at Day 29 and 514.6 BAU/mL at Day 43, decreasing to 61.0 BAU/mL at Day 197. BNT162b2 induced higher antibody levels at all time points. The NT50 GMT ratio (HXP-GPOVac/BNT162b2) at Day 43 was 0.51 (95% CI: 0.39–0.67); the lower bound did not exceed the prespecified non-inferiority margin of 0.5, and non-inferiority was not established. Seroconversion rates at Day 43 were 97.6% for HXP-GPOVac and 97.1% for BNT162b2 (neutralizing antibody) and 98.6% and 97.1%, respectively (anti-spike IgG). ELISpot analyses demonstrated increased IFN-γ responses after the second dose without evidence of Th2-dominant skewing. Conclusions: HXP-GPOVac was well tolerated and induced substantial humoral and cellular immune responses, with high seroconversion rates and balanced T-cell polarization. Although absolute antibody levels were lower than those induced by BNT162b2 and the prespecified non-inferiority criterion was not met, these findings support continued evaluation of the inactivated NDV-HXP-S vaccine platform.

14 August 2025 in PLOS ONE
Verified
Journal Article
Open access
KPKriengkrai Prasert
Kriengkrai Prasert
PPPrabda Praphasiri
Prabda Praphasiri
DDDarunee Ditsungnoen
Darunee Ditsungnoen
SSSribud Srichaijaroonpong
Sribud Srichaijaroonpong
RURatchadaporn Ungcharoen
Ratchadaporn Ungcharoen
MMMartha P. Montgomery
Martha P. Montgomery
Background: Influenza and COVID-19 vaccinations are recommended for health care personnel (HCP) in Thailand, but uptake depends on HCP perceptions and motivations. Methods: To assess factors associated with self-reported influenza vaccination in the most recent season and intention to receive future COVID-19 vaccination annually, HCP from 16 hospitals across eight Thailand provinces were surveyed during December 2023 through January 2024. Additional survey variables included demographic and occupational characteristics, prior experiences with vaccination, perceptions of disease severity and vaccine safety and effectiveness. Multilevel mixed effect multivariable logistic regression was used, accounting for variability at provincial and hospital levels. Results: Overall, 2,180 HCP were surveyed. Three-quarters (74.8%) reported influenza vaccination in the most recent season, and 58.1% intended to receive COVID-19 vaccination annually in the future. Previous influenza vaccination was strongly associated with reported vaccination in the current season (adjusted odds ratio [aOR] 2.94, 95% confidence interval [CI] 2.68–3.23). For future COVID-19 vaccination, perceived vaccine safety was strongly associated (aOR 3.49, 95% CI 3.18–3.84). Perceived disease severity was higher for COVID-19 than for influenza, but perceived vaccine safety and effectiveness were higher for influenza than for COVID-19. The most common barrier to influenza vaccination was insufficient time to get vaccinated (23.7%); whereas the most common barrier for COVID-19 vaccination was vaccine safety concern (30.0%). Conclusions: Improving vaccination coverage among HCP might need different approaches for influenza and COVID-19 vaccines. Improving convenience might be especially important for increasing influenza vaccination coverage, whereas providing reassurance about COVID-19 vaccine safety might be especially important for COVID-19.